Futura Medical plc (AIM: FUM), a provider of consumer healthcare products, announced on Wednesday that it has successfully completed its WSD4000 Home User study, which demonstrated positive outcomes for the treatment of sexual dysfunction in women. The study, involving 67 women, showed a significant improvement in sexual function after four weeks of use, with many participants reporting increased vaginal lubrication, genital sensation, pleasure and overall satisfaction.

The study's results indicated a strong user response, with 57% of women using the product more frequently than the recommended minimum. Among those with sexual dysfunction, notable improvements were observed in arousal, lubrication, orgasm, satisfaction and discomfort (pain).

Following these promising results, Futura's Board has recommended proceeding with an Early Feasibility Study in H1 2025. This will further refine the product's methodology and assess its efficacy in a broader population.

WSD4000 is a topical treatment designed to address common symptoms of sexual dysfunction in women, such as lack of arousal, lubrication and desire. There is currently no regulatory-approved, over-the-counter topical treatment for women's sexual dysfunction. Market research indicates a significant opportunity, as 40%-50% of women experience some form of sexual dysfunction, with 60% of those affected reporting symptoms in the last year. Despite this, only a quarter seek professional help, and many see little improvement over time.

Futura Medical's portfolio also includes Eroxon, a clinically proven topical treatment for erectile dysfunction (ED), with strong market presence through distribution partners like Haleon and Cooper Consumer Health.